Voglibose

Summary

Voglibose (CHEMBL476960) is an approved small molecule (ATC A10BF03); indicated across 2 conditions including diabetes mellitus and type 2 diabetes mellitus.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: A10BF03
• Indications: 2 conditions
• Clinical trials: 17
• Chemistry: 267.28 Da · C10H21NO7

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL476960
Name	Voglibose
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	444020
ATC	A10BF03
Molecular formula	C10H21NO7
Molecular weight	267.28
InChIKey	FZNCGRZWXLXZSZ-CIQUZCHMSA-N

SMILES: C1[C@@H]([C@@H]([C@H]([C@@H]([C@]1(CO)O)O)O)O)NC(CO)CO

IUPAC name: (1S,2S,3R,4S,5S)-5-(1,3-dihydroxypropan-2-ylamino)-1-(hydroxymethyl)cyclohexane-1,2,3,4-tetrol

Also known as: A-71100, AO-128, Basen, Voglibosa, Voglibose, VOGLIBOSE, voglibose, SID144205773, SID170465993

Patent coverage: 36,890 distinct patent families (78,659 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 6 (assay-derived). Sample: Maltase-glucoamylase, Lysosomal alpha-glucosidase, Sucrase-isomaltase, intestinal, Lysosomal alpha-glucosidase, Glycogen debranching enzyme, Alpha-glucosidase.

Bioactivity

ChEMBL activities: 28 potent at pChembl ≥ 5 of 30 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
P23739	7.16	IC50	70	nM	CHEMBL_ACT_2556868
GAA	7.16	IC50	70	nM	CHEMBL_ACT_2556928
Q6P7A9	6.96	IC50	110	nM	CHEMBL_ACT_2556846
Q6P7A9	6.92	IC50	120	nM	CHEMBL_ACT_12146672
Q6P7A9	6.92	IC50	120	nM	CHEMBL_ACT_15063067
P23739	6.8	IC50	160	nM	CHEMBL_ACT_2556854
Q6P7A9	6.75	IC50	180	nM	CHEMBL_ACT_5140283
P23739	6.7	IC50	200	nM	CHEMBL_ACT_25063532
P23739	6.7	IC50	200	nM	CHEMBL_ACT_5245461
Q6P7A9	6.7	IC50	200	nM	CHEMBL_ACT_6164308
P23739	6.7	IC50	200	nM	CHEMBL_ACT_6176795
P23739	6.52	IC50	300	nM	CHEMBL_ACT_16480736
P23739	6.43	IC50	370	nM	CHEMBL_ACT_12148404
P23739	6.43	IC50	370	nM	CHEMBL_ACT_15063088
P23739	6.43	IC50	370	nM	CHEMBL_ACT_5140316
Q6P7A9	5.92	IC50	1200	nM	CHEMBL_ACT_25063548
Q6P7A9	5.92	IC50	1200	nM	CHEMBL_ACT_5245447
P23739	5.92	IC50	1200	nM	CHEMBL_ACT_6164319
Q6P7A9	5.92	IC50	1200	nM	CHEMBL_ACT_6176787
MGAM	5.89	IC50	1300	nM	CHEMBL_ACT_16616250
MGAM	5.89	IC50	1300	nM	CHEMBL_ACT_22445277
P23739	5.68	IC50	2100	nM	CHEMBL_ACT_5245475
P23739	5.68	IC50	2100	nM	CHEMBL_ACT_6164293
P23739	5.68	IC50	2100	nM	CHEMBL_ACT_6176803
P23739	5.28	IC50	5200	nM	CHEMBL_ACT_12148406
P23739	5.28	IC50	5200	nM	CHEMBL_ACT_15063078
P23739	5.28	IC50	5200	nM	CHEMBL_ACT_5140295
GAA	5.25	IC50	5600	nM	CHEMBL_ACT_2556882

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 indications (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
diabetes mellitus	4	MONDO:0005015	EFO:0000400
type 2 diabetes mellitus	3	MONDO:0005148	MONDO:0005148

Clinical trials

Total trials: 17.

Phase distribution

Phase	Trials
PHASE4	6
PHASE3	4
Not specified	3
PHASE2/PHASE3	2
PHASE2	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00663884	PHASE4	COMPLETED	Glufast On Insulin Glargine Trial in Type 2 DM
NCT00970528	PHASE4	COMPLETED	Glucose Reduction by Early Acarbose Treatment in Basal Insulin
NCT01309698	PHASE4	COMPLETED	Drug Interaction of Vildagliptin (LAF237) With Voglibose in Japanese Patients With Type 2 Diabetes
NCT02049814	PHASE4	COMPLETED	Efficacy and Safety of Voglibose Compared With Acarbose in Participants With Type 2 Diabetes
NCT02097342	PHASE4	UNKNOWN	Effect of Linagliptin on Insulin Sensitivity and Pancreatic Beta Cell Function in Patients With Type 2 Diabetes Mellitus
NCT02287402	PHASE4	COMPLETED	Postmarketing Clinical Study on AO-128
NCT00411554	PHASE3	COMPLETED	A Study of Sitagliptin in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Diet/Exercise Therapy (0431-054)(COMPLETED)
NCT00654381	PHASE3	COMPLETED	Japanese P III vs Voglibose and Placebo
NCT00837577	PHASE3	COMPLETED	MK0431/ONO-5435 Phase III Clinical Trial -Add-on to Voglibose Study for Patients With Type 2 Diabetes Mellitus (MK0431-104)
NCT01263483	PHASE2/PHASE3	COMPLETED	Efficacy and Safety of Alogliptin Used in Combination With α-glucosidase Inhibitor in Participants With Type 2 Diabetes in Japan
NCT01263509	PHASE2/PHASE3	COMPLETED	Long-term Safety Study of Alogliptin Used in Combination With α-glucosidase Inhibitor in Participants With Type 2 Diabetes in Japan
NCT05688332	PHASE3	UNKNOWN	Glycaemic & Cardiovascular Treatment Outcomes of Voglibose Vs Glibenclamide Added to Metformin in T2DM Patients
NCT01263470	PHASE2	COMPLETED	Efficacy and Safety of Alogliptin in Participants With Type 2 Diabetes in Japan
NCT01263496	PHASE2	COMPLETED	Long-term Safety Study of Alogliptin in Participants With Type 2 Diabetes in Japan
NCT00212017	Not specified	TERMINATED	Assessment of an Alpha-glucosidase Inhibitor to Block Cardiac Events in Patients With MI and IGT
NCT00724542	Not specified	UNKNOWN	Evaluation of Intervention on Impaired Glucose Tolerance(IGT) in Patients With Coronary Heart Disease.
NCT01993927	Not specified	COMPLETED	Voglibose Tablets 0.2 / OD Tablets 0.2 Special Drug Use Surveillance Long-term Use in Patients With Impaired Glucose Tolerance

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).